Appendix E Reporting proforma for lung cancer biopsy/cytology specimens

Surname………………………... Forenames…………………………...… Date of birth………... Sex…....

Hospital………….……….……… Hospital no……………….………………. NHS/CHI no………….………

Date of procedure………….……... Date of report authorisation……………. Report no…………….….........

Date of receipt………….………. Pathologist……….………………………. Clinician……………….……......

**Previous treatment (neoadjuvant chemotherapy/radiotherapy)\*** Yes No Not known

**Specimen origin\***

Right lung, NOS Left lung, NOS Right lower lobe

Right upper lobe Right middle lobe Other ………….

Left upper lobe Left lower lobe Not known

**Sample type\* (more than one box may be ticked)**

\*It is recommended that residual positive cytology samples be processed to histology blocks for potential further analysis.

Biopsy

Endobronchial biopsy

Transbronchial biopsy

Transthoracic needle biopsy

Lymph node biopsy Specify site(s) ……..…………….…........

Pleural biopsy

Other metastatic site(s) Details .........……………….....................

Cytology

Transthoracic FNA lung

Bronchial washings/traps/lavages

Bronchial brushings

Transbronchial or endoscopic needle aspirate Details of site(s) ………..……………......

Pleural fluid

Other cytology Specify…..........…………...………....…..

**Microscopic features**

**Histological/cytological type†**

Adenocarcinoma (*morphological adenocarcinoma patterns clearly present)*

Specify patterns present or variants ..........………………………………………………..........

Non-small cell carcinoma, favour adenocarcinoma *(morphological adenocarcinoma patterns not
present but adenocarcinomatous differentiation supported by stains such as TTF-1, D-PAS)*

Squamous cell carcinoma *(morphological squamous cell patterns clearly present)*

Non-small cell carcinoma, favour squamous cell carcinoma *(morphological squamous cell
patterns not present but squamous differentiation supported by stains such as p40, CK5/6)*

Small cell carcinoma

Non-small cell carcinoma, not otherwise specified

Non-small cell carcinoma with neuroendocrine morphology (NE markers positive)

Non-small cell carcinoma with neuroendocrine morphology (NE markers negative)

Non-small cell carcinoma, not otherwise specified, possible adenosquamous carcinoma
*(when both glandular and squamous components are morphologically present or
both are suggested by special stains)*

Non-small cell carcinoma with spindle and/or giant cell carcinoma and/or pleomorphic features
*(mention if adenocarcinoma or squamous carcinoma are present morphologically or with stains)*

Evidence of differentiation if pleomorphic NSCC …………………………………………………………………….

Combined tumour (Specify) ………………………………………………………………………………….

Other tumour (Specify, e.g. carcinoid, etc.) ……………………........................................………..

**Ancillary data**

Epidermal growth factor (EGFR) mutation present Yes No Not assessed

ALK translocation present Yes No Not assessed

PD-L1 status % age of tumour cells positive …… Antibody used …… Not assessed

PD-L1 test Commercial assay (companion diagnostic) Laboratory derived test (LDT)

**SNOMED codes:**

**Comments**

Signature .............……………………………………………….

**Date ……..../….….../……....**

*Note:*

†Data items that are currently part of the Cancer Outcomes and Services Dataset (COSD) v7.